Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free CRBU Stock Alerts

Caribou Biosciences (CRBU) Financials

Caribou Biosciences logo
$1.84 +0.03 (+1.37%)
As of 11:15 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Caribou Biosciences

Annual Income Statements for Caribou Biosciences

This table shows Caribou Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -34 -67 -99 -102 -149 -148
Consolidated Net Income / (Loss)		 -23 -34 -67 -99 -102 -149 -148
Net Income / (Loss) Continuing Operations		 -23 -34 -67 -99 -102 -149 -148
Total Pre-Tax Income 		-31 -36 -67 -99 -102 -149 -149
Total Operating Income		 -34 -36 -67 -106 -116 -167 -148
Total Gross Profit		 5.79 12 9.60 14 34 9.99 11
Total Revenue		 5.79 12 9.60 14 34 9.99 11
Operating Revenue		 5.79 12 9.60 14 34 9.99 11
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 40 48 77 120 151 177 160
Selling, General & Admin Expense		 16 14 24 38 38 46 38
Research & Development Expense		 24 34 52 82 112 130 109
Impairment Charge		 - - - - - 0.00 12
Total Other Income / (Expense), net		 3.34 -0.00 0.38 7.05 14 18 -0.33
Other Income / (Expense), net		 2.29 -0.22 -1.21 7.05 14 18 -0.33
Income Tax Expense		 -7.54 -1.82 0.32 0.07 0.19 -0.01 -0.55
Basic Earnings per Share		 ($2.80) ($4.01) ($2.11) ($1.64) ($1.38) ($1.65) ($1.59)
Weighted Average Basic Shares Outstanding		 8.37M 8.55M 31.66M 60.80M 73.81M 90.32M 93.39M
Diluted Earnings per Share		 ($2.80) ($4.01) ($2.11) ($1.64) ($1.38) ($1.65) ($1.59)
Weighted Average Diluted Shares Outstanding		 8.37M 8.55M 31.66M 60.80M 73.81M 90.32M 93.39M
Weighted Average Basic & Diluted Shares Outstanding		 8.37M 8.55M 31.66M 61.30M 90.31M 93.00M 96.64M

Quarterly Income Statements for Caribou Biosciences

This table shows Caribou Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -10 -35 -41 -38 -35 -35 -40 -54 -28 -26 -25
Consolidated Net Income / (Loss)		 -10 -35 -41 -38 -35 -35 -40 -54 -28 -26 -25
Net Income / (Loss) Continuing Operations		 -10 -35 -41 -38 -35 -35 -40 -54 -28 -26 -25
Total Pre-Tax Income 		-10 -34 -41 -38 -35 -35 -40 -54 -28 -27 -25
Total Operating Income		 -15 -37 -46 -44 -38 -39 -43 -48 -29 -28 -26
Total Gross Profit		 24 3.56 2.43 3.46 2.02 2.08 2.35 2.67 2.20 3.94 2.40
Total Revenue		 24 3.56 2.43 3.46 2.02 2.08 2.35 2.67 2.20 3.94 2.40
Operating Revenue		 24 3.56 2.43 3.46 2.02 2.08 2.35 2.67 2.20 3.94 2.40
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 38 41 48 47 40 41 45 50 32 32 29
Selling, General & Admin Expense		 9.71 9.72 15 11 9.84 10 9.74 10 9.20 8.58 8.07
Research & Development Expense		 29 31 34 35 30 30 36 28 22 24 21
Total Other Income / (Expense), net		 4.63 3.13 4.77 5.80 3.55 3.38 2.92 -6.52 1.85 1.42 1.20
Other Income / (Expense), net		 4.63 3.13 4.77 5.80 3.55 3.38 2.92 -6.52 1.85 1.42 1.20
Basic Earnings per Share		 ($0.12) ($0.32) ($0.46) ($0.42) ($0.38) ($0.39) ($0.43) ($0.58) ($0.30) ($0.28) ($0.26)
Weighted Average Basic Shares Outstanding		 83.78M 73.81M 89.30M 90.34M 90.46M 90.32M 92.68M 93.03M 93.29M 93.39M 95.86M
Diluted Earnings per Share		 ($0.12) ($0.32) ($0.46) ($0.42) ($0.38) ($0.39) ($0.43) ($0.58) ($0.30) ($0.28) ($0.26)
Weighted Average Diluted Shares Outstanding		 83.78M 73.81M 89.30M 90.34M 90.46M 90.32M 92.68M 93.03M 93.29M 93.39M 95.86M
Weighted Average Basic & Diluted Shares Outstanding		 88.43M 90.31M 90.32M 90.36M 90.55M 93.00M 93.00M 93.12M 93.47M 96.64M 99.18M

Annual Cash Flow Statements for Caribou Biosciences

This table details how cash moves in and out of Caribou Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.60 -25 225 -182 -7.18 -35 -3.93
Net Cash From Operating Activities		 -32 -33 -33 -91 -93 -138 -111
Net Cash From Continuing Operating Activities		 -32 -33 -33 -91 -93 -138 -111
Net Income / (Loss) Continuing Operations		 -23 -34 -67 -99 -102 -149 -148
Consolidated Net Income / (Loss)		 -23 -34 -67 -99 -102 -149 -148
Depreciation Expense		 0.75 0.90 0.98 1.62 3.53 3.93 3.65
Amortization Expense		 0.00 0.00 0.05 -0.80 -4.43 -4.73 -1.14
Non-Cash Adjustments To Reconcile Net Income		 -1.90 -0.48 2.72 14 17 19 36
Changes in Operating Assets and Liabilities, net		 -7.43 0.67 31 -5.87 -6.85 -7.54 -1.42
Net Cash From Investing Activities		 27 6.36 -176 -93 -68 87 102
Net Cash From Continuing Investing Activities		 27 6.36 -176 -93 -68 87 102
Purchase of Property, Plant & Equipment		 -0.88 -0.32 -2.12 -6.45 -12 -4.88 -1.36
Acquisitions		 0.00 -1.00 -1.00 -0.60 0.00 -1.63 0.00
Purchase of Investments		 0.00 0.00 -173 -339 -395 -304 -149
Sale of Property, Plant & Equipment		 0.00 0.01 - - 0.00 0.01 0.00
Sale and/or Maturity of Investments		 28 7.67 0.00 253 338 397 253
Net Cash From Financing Activities		 0.17 1.74 433 2.13 154 17 4.82
Net Cash From Continuing Financing Activities		 0.17 1.74 433 2.13 154 17 4.82
Issuance of Common Equity		 0.00 0.00 321 0.00 18 16 4.82
Other Financing Activities, net		 0.22 0.27 2.43 2.13 136 0.62 0.01

Quarterly Cash Flow Statements for Caribou Biosciences

This table details how cash moves in and out of Caribou Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 38 -53 -1.76 -12 -5.90 -16 13 -4.22 -14 1.22 -0.30
Net Cash From Operating Activities		 -29 -21 -37 -33 -33 -35 -37 -28 -25 -21 -27
Net Cash From Continuing Operating Activities		 -29 -21 -37 -33 -33 -35 -37 -28 -25 -21 -27
Net Income / (Loss) Continuing Operations		 -10 -35 -41 -38 -35 -35 -40 -54 -28 -26 -25
Consolidated Net Income / (Loss)		 -10 -35 -41 -38 -35 -35 -40 -54 -28 -26 -25
Depreciation Expense		 1.58 0.74 0.71 0.86 1.18 1.18 1.17 1.17 0.63 0.68 0.65
Amortization Expense		 -2.44 1.62 -1.54 -0.95 -1.22 -1.02 -0.45 -0.29 -0.24 -0.16 -0.27
Non-Cash Adjustments To Reconcile Net Income		 3.83 4.30 6.47 3.85 4.90 1.86 4.73 25 2.48 3.91 2.99
Changes in Operating Assets and Liabilities, net		 -22 6.47 -1.61 1.07 -2.84 -2.01 -2.18 0.05 -0.52 1.23 -5.27
Net Cash From Investing Activities		 -68 -31 23 21 27 16 49 24 11 18 24
Net Cash From Continuing Investing Activities		 -68 -31 23 21 27 16 49 24 11 18 24
Purchase of Property, Plant & Equipment		 -4.75 -2.28 -1.45 -2.24 -0.67 -0.52 -1.04 -0.42 -0.12 0.22 -0.07
Purchase of Investments		 -176 -84 -71 -84 -93 -56 -16 -32 -57 -44 -22
Sale and/or Maturity of Investments		 112 55 97 108 121 72 66 57 68 62 46
Net Cash From Financing Activities		 135 -0.04 12 0.13 0.24 3.86 0.47 0.01 0.28 4.07 2.70
Net Cash From Continuing Financing Activities		 135 -0.04 12 0.13 0.24 3.86 0.47 0.01 0.28 4.07 2.70
Issuance of Common Equity		 -0.16 - 12 0.00 0.24 3.86 0.47 - 0.28 4.07 2.69
Other Financing Activities, net		 135 -0.04 0.49 0.13 - -0.00 0.00 0.01 - - 0.01

Annual Balance Sheets for Caribou Biosciences

This table presents Caribou Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 36 442 374 432 313 175
Total Current Assets		 24 391 260 339 219 145
Cash & Equivalents		 16 240 58 51 16 12
Short-Term Investments		 0.00 135 189 278 193 127
Accounts Receivable		 3.83 6.64 2.42 2.43 2.09 1.97
Prepaid Expenses		 3.19 7.24 7.92 6.16 6.59 2.91
Other Current Assets		 1.33 1.49 2.25 1.43 1.16 1.01
Plant, Property, & Equipment, net		 3.50 4.89 11 18 19 6.76
Total Noncurrent Assets		 8.24 46 103 75 75 23
Long-Term Investments		 7.63 45 77 51 49 3.51
Other Noncurrent Operating Assets		 0.61 0.98 26 24 26 20
Total Liabilities & Shareholders' Equity		 36 442 374 432 313 175
Total Liabilities		 18 55 73 64 60 53
Total Current Liabilities		 12 26 28 28 31 25
Accounts Payable		 2.60 3.99 1.15 3.12 2.48 5.78
Accrued Expenses		 8.97 13 16 21 24 17
Current Deferred Revenue		 0.16 8.70 9.94 2.85 3.13 1.90
Other Current Liabilities		 0.65 0.00 0.97 1.20 1.43 1.20
Total Noncurrent Liabilities		 5.77 29 45 36 30 28
Noncurrent Deferred Revenue		 1.86 24 16 6.10 3.32 1.75
Other Noncurrent Operating Liabilities		 2.83 4.10 28 29 26 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -23 388 301 368 253 122
Total Preferred & Common Equity		 -23 388 301 368 253 122
Total Common Equity		 -23 388 301 368 253 122
Common Stock		 7.43 486 500 668 701 719
Retained Earnings		 -31 -98 -197 -299 -448 -597
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.14 -1.52 0.03 0.26 0.10

Quarterly Balance Sheets for Caribou Biosciences

This table presents Caribou Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 458 407 373 344 274 221 195 149
Total Current Assets		 351 305 271 237 217 193 156 122
Cash & Equivalents		 104 49 38 32 29 25 11 12
Short-Term Investments		 234 245 224 196 179 159 136 106
Accounts Receivable		 3.48 2.64 1.94 1.87 1.93 2.03 2.07 1.67
Prepaid Expenses		 7.07 6.91 6.32 6.58 6.12 5.78 5.32 2.39
Other Current Assets		 1.66 0.97 0.97 0.80 0.81 0.75 0.86 0.69
Plant, Property, & Equipment, net		 17 19 20 20 19 8.18 7.60 6.12
Total Noncurrent Assets		 90 83 82 87 38 20 32 20
Long-Term Investments		 66 60 59 62 13 0.13 12 1.00
Other Noncurrent Operating Assets		 24 23 23 25 25 20 20 19
Total Liabilities & Shareholders' Equity		 458 407 373 344 274 221 195 149
Total Liabilities		 59 64 62 63 56 55 53 47
Total Current Liabilities		 25 29 31 32 28 29 28 20
Accounts Payable		 2.38 5.94 3.23 2.70 3.87 3.24 3.80 3.50
Accrued Expenses		 18 19 24 25 20 21 19 14
Current Deferred Revenue		 2.83 2.83 2.83 2.83 2.83 2.83 2.22 0.99
Other Current Liabilities		 1.14 1.26 1.26 1.18 1.90 2.29 2.69 1.29
Total Noncurrent Liabilities		 35 35 32 31 27 26 25 27
Noncurrent Deferred Revenue		 6.73 5.43 4.60 3.95 2.62 1.77 1.76 1.65
Other Noncurrent Operating Liabilities		 28 29 26 26 24 24 23 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 398 343 310 281 217 166 142 102
Total Preferred & Common Equity		 398 343 310 281 217 166 142 102
Total Common Equity		 398 343 310 281 217 166 142 102
Common Stock		 664 684 689 693 705 709 712 724
Retained Earnings		 -265 -341 -378 -413 -488 -542 -570 -622
Accumulated Other Comprehensive Income / (Loss)		 -0.98 -0.32 -0.32 0.79 0.17 0.04 0.09 -0.02

Annual Metrics And Ratios for Caribou Biosciences

This table displays calculated financial ratios and metrics derived from Caribou Biosciences' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 60,192,061.00 61,001,561.00 88,431,136.00 - 93,468,038.00
DEI Adjusted Shares Outstanding		 0.00 0.00 60,192,061.00 61,001,561.00 88,431,136.00 - 93,468,038.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.11 -1.63 -1.15 - -1.58
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 113.56% -22.35% 44.31% 148.91% -71.01% 11.66%
EBITDA Growth		 0.00% -13.38% -89.46% -46.73% -4.31% -45.86% 2.50%
EBIT Growth		 0.00% -13.53% -87.62% -45.71% -2.54% -46.37% 0.29%
NOPAT Growth		 0.00% -5.30% -85.41% -58.85% -9.08% -43.56% 10.97%
Net Income Growth		 0.00% -46.42% -95.07% -48.56% -2.66% -46.08% 0.66%
EPS Growth		 0.00% -43.21% 47.38% 22.27% 15.85% -19.57% 3.64%
Operating Cash Flow Growth		 0.00% -3.78% 2.10% -179.73% -2.56% -48.14% 19.69%
Free Cash Flow Firm Growth		 0.00% 0.00% 10.59% -357.48% -11.23% -31.42% 27.55%
Invested Capital Growth		 0.00% 0.00% -598.45% 28.36% 50.74% 51.42% -261.93%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 8.91% -0.39% -12.91% 20.05%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -11.51% -4.73% -2.31% 5.69%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -10.51% -7.82% -0.80% 5.38%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.95% -6.29% -0.87% 6.56%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -9.36% -7.95% -0.67% 5.73%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -2,242.86% 8.00% -4.43% 6.47%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -69.32% -4.19% 3.78% -11.35% 11.66%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 3.24% -8.81% 13.46%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 9.04% -89.55% 37.13% -18.05%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -540.08% -286.73% -699.62% -711.33% -298.10% -1,500.03% -1,309.88%
Operating Margin		 -592.69% -292.24% -697.84% -768.17% -336.63% -1,667.16% -1,329.37%
EBIT Margin		 -553.06% -294.01% -710.42% -717.28% -295.49% -1,492.04% -1,332.33%
Profit (Net Income) Margin		 -404.82% -277.55% -697.26% -717.79% -296.05% -1,491.95% -1,327.40%
Tax Burden Percent		 75.66% 94.97% 100.48% 100.07% 100.19% 99.99% 99.63%
Interest Burden Percent		 96.74% 99.41% 97.68% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -191.81% -32.99% -28.87% -30.50% -47.99% -78.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -100.82% -28.51% -24.35% -25.28% -40.00% -60.85%
Return on Assets (ROA)		 0.00% -95.18% -27.98% -24.36% -25.33% -40.00% -60.62%
Return on Common Equity (ROCE)		 0.00% 251.35% -29.63% -28.87% -30.50% -47.99% -78.97%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 146.38% -17.26% -33.04% -27.71% -58.95% 0.00%
Net Operating Profit after Tax (NOPAT)		 -24 -25 -47 -74 -81 -117 -104
NOPAT Margin		 -414.88% -204.57% -488.49% -537.72% -235.64% -1,167.01% -930.56%
Net Nonoperating Expense Percent (NNEP)		 0.00% -79.64% -9.03% -6.69% -5.91% -10.17% -22.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -22.05% -46.11% -84.99%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 284.35% 113.74% 253.41% 274.49% 111.56% 464.85% 339.76%
R&D to Revenue		 408.34% 278.50% 544.44% 593.68% 325.07% 1,302.31% 980.72%
Operating Expenses to Revenue		 692.69% 392.24% 797.84% 868.17% 436.63% 1,767.16% 1,429.37%
Earnings before Interest and Taxes (EBIT)		 -32 -36 -68 -99 -102 -149 -149
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -35 -67 -99 -103 -150 -146
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.34 1.27 0.00 0.57 1.22
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.34 1.27 0.00 0.57 1.22
Price to Revenue (P/Rev)		 37.32 17.47 94.63 27.66 0.00 14.41 13.32
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 18.98 50.76 4.21 0.00 0.00 0.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.05 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.05 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.27 -1.09 -1.08 -1.05 -1.03 -1.07
Leverage Ratio		 0.00 2.02 1.18 1.19 1.20 1.20 1.30
Compound Leverage Factor		 0.00 2.00 1.15 1.19 1.20 1.20 1.30
Debt to Total Capital		 0.00% 4.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 4.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 219.69% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -124.60% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.64 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.03 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.90 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.35 10.19 2.32 0.00 -1.39 -5.00
Noncontrolling Interest Sharing Ratio		 0.00% 231.04% 10.19% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 1.96 15.15 9.25 11.97 7.16 5.71
Quick Ratio		 0.00 1.60 14.81 8.89 11.70 6.90 5.56
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -21 -18 -84 -93 -123 -89
Operating Cash Flow to CapEx		 -3,620.59% -10,819.22% -1,533.19% -1,409.45% -803.33% -2,839.53% -8,167.18%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,025.89 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -8,001.50 -1,660.75 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -8,222.50 -1,676.10 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.34 0.04 0.03 0.09 0.03 0.05
Accounts Receivable Turnover		 0.00 3.23 1.83 3.06 14.21 4.42 5.49
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 3.53 2.29 1.78 2.38 0.53 0.86
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 113.15 199.04 119.28 25.68 82.67 66.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 113.15 199.04 119.28 25.68 82.67 66.50
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -4.77 -33 -24 -12 -5.71 -21
Invested Capital Turnover		 0.00 -5.18 -0.50 -0.48 -1.94 -1.14 -0.85
Increase / (Decrease) in Invested Capital		 0.00 -4.77 -29 9.45 12 6.05 -15
Enterprise Value (EV)		 0.00 235 487 58 0.00 -115 5.77
Market Capitalization		 216 216 908 383 0.00 144 149
Book Value per Share		 $0.00 ($2.74) $6.44 $4.93 $4.99 $2.79 $1.31
Tangible Book Value per Share		 $0.00 ($2.74) $6.44 $4.93 $4.99 $2.79 $1.31
Total Capital		 0.00 19 388 301 368 253 122
Total Debt		 0.00 0.92 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.92 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -23 -421 -325 -380 -259 -143
Capital Expenditures (CapEx)		 0.88 0.31 2.12 6.45 12 4.87 1.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.04 -10 -16 -18 -21 -20
Debt-free Net Working Capital (DFNWC)		 0.00 12 365 232 311 189 120
Net Working Capital (NWC)		 0.00 12 365 232 311 189 120
Net Nonoperating Expense (NNE)		 -0.58 9.02 20 25 21 32 44
Net Nonoperating Obligations (NNO)		 0.00 -23 -421 -325 -380 -259 -143
Total Depreciation and Amortization (D&A)		 0.75 0.90 1.04 0.83 -0.90 -0.80 2.51
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -32.65% -109.07% -112.22% -53.04% -208.23% -174.94%
Debt-free Net Working Capital to Revenue		 0.00% 96.41% 3,806.66% 1,675.84% 900.71% 1,888.39% 1,073.73%
Net Working Capital to Revenue		 0.00% 96.41% 3,806.66% 1,675.84% 900.71% 1,888.39% 1,073.73%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.11) ($1.64) ($1.38) ($1.65) ($1.59)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 60.66M 60.80M 73.81M 90.32M 93.39M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.11) ($1.64) ($1.38) ($1.65) ($1.59)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 60.66M 60.80M 73.81M 90.32M 93.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.11) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 31.66M 61.30M 90.31M 93.00M 96.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -25 -47 -74 -81 -117 -95
Normalized NOPAT Margin		 -414.88% -204.57% -488.49% -537.72% -235.64% -1,167.01% -854.34%
Pre Tax Income Margin		 -535.04% -292.27% -693.92% -717.28% -295.49% -1,492.04% -1,332.33%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -8,002.75 -1,817.15 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -6,003.38 -1,264.34 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -8,223.75 -1,832.50 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -6,224.38 -1,279.69 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Caribou Biosciences

This table displays calculated financial ratios and metrics derived from Caribou Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 88,284,776.00 88,431,136.00 90,314,501.00 90,317,771.00 90,362,771.00 - 93,004,602.00 93,004,602.00 93,123,239.00 93,468,038.00 96,637,202.00
DEI Adjusted Shares Outstanding		 88,284,776.00 88,431,136.00 90,314,501.00 90,317,771.00 90,362,771.00 - 93,004,602.00 93,004,602.00 93,123,239.00 93,468,038.00 96,637,202.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.11 -0.39 -0.46 -0.42 -0.38 - -0.43 -0.58 -0.30 -0.28 -0.26
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 616.38% -3.63% -30.64% -7.75% -91.45% -41.62% -3.13% -23.01% 8.60% 89.74% 1.87%
EBITDA Growth		 59.05% -16.98% -45.30% -21.87% -219.59% -10.57% 6.62% -40.85% 21.82% 24.95% 37.10%
EBIT Growth		 62.46% -27.46% -47.03% -27.70% -246.77% -3.46% 3.01% -43.51% 20.57% 23.83% 37.27%
NOPAT Growth		 44.86% -22.45% -47.84% -32.35% -161.31% -3.83% 6.71% -9.37% 23.11% 26.81% 38.76%
Net Income Growth		 62.46% -27.85% -47.03% -27.70% -246.77% -2.85% 3.01% -43.51% 20.57% 25.36% 37.27%
EPS Growth		 72.73% 27.27% 0.00% 12.50% -216.67% -21.88% 6.52% -38.10% 21.05% 28.21% 39.53%
Operating Cash Flow Growth		 -28.66% 14.63% -33.16% -116.44% -13.45% -65.91% 1.28% 14.02% 22.89% 41.29% 26.52%
Free Cash Flow Firm Growth		 1.94% -24.20% -50.37% -180.13% 21.11% 13.20% 13.80% 48.80% 49.11% 85.09% 83.97%
Invested Capital Growth		 76.36% 50.74% 49.07% 65.63% -46.47% 51.42% 61.08% -69.40% -92.76% -261.93% -310.71%
Revenue Q/Q Growth		 530.15% -84.96% -31.73% 42.61% -41.57% 2.62% 13.29% 13.34% -17.59% 79.30% -39.18%
EBITDA Q/Q Growth		 64.95% -194.06% -31.63% 10.17% 8.09% -1.74% -11.17% -35.51% 48.99% 2.34% 6.83%
EBIT Q/Q Growth		 66.12% -243.05% -20.17% 8.58% 7.99% -2.35% -12.65% -35.28% 49.08% 1.85% 7.22%
NOPAT Q/Q Growth		 55.48% -155.87% -22.86% 5.44% 12.10% -1.67% -10.39% -10.87% 38.21% 3.22% 7.64%
Net Income Q/Q Growth		 66.12% -244.98% -19.50% 8.58% 7.99% -2.32% -12.68% -35.28% 49.08% 3.85% 5.30%
EPS Q/Q Growth		 75.00% -166.67% -43.75% 8.70% 9.52% -2.63% -10.26% -34.88% 48.28% 6.67% 7.14%
Operating Cash Flow Q/Q Growth		 -89.58% 25.74% -74.02% 11.66% 0.62% -8.60% -3.54% 23.06% 10.87% 17.32% -29.58%
Free Cash Flow Firm Q/Q Growth		 -67.33% -26.56% -10.17% -20.07% 52.88% -39.24% -9.40% 28.68% 53.17% 59.21% -17.61%
Invested Capital Q/Q Growth		 79.88% -89.55% 11.62% -1.97% 14.26% 37.13% 29.19% -343.82% 2.44% -18.05% 19.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -45.93% -898.12% -1,731.70% -1,090.85% -1,715.91% -1,701.16% -1,669.27% -1,995.65% -1,235.30% -672.82% -1,030.66%
Operating Margin		 -61.84% -1,052.33% -1,893.87% -1,255.80% -1,889.23% -1,871.69% -1,823.76% -1,783.95% -1,337.58% -721.97% -1,096.37%
EBIT Margin		 -42.27% -964.36% -1,697.57% -1,088.25% -1,713.64% -1,709.15% -1,699.58% -2,028.42% -1,253.32% -686.07% -1,046.52%
Profit (Net Income) Margin		 -42.27% -969.79% -1,697.57% -1,088.25% -1,713.64% -1,708.71% -1,699.58% -2,028.42% -1,253.32% -672.11% -1,046.52%
Tax Burden Percent		 100.00% 100.56% 100.00% 100.00% 100.00% 99.97% 100.00% 100.00% 100.00% 97.97% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -26.18% -30.50% -37.09% -42.57% -43.60% -47.99% -52.76% -68.93% -74.28% -78.97% -83.46%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -3.42% -82.50% -150.36% -99.74% -49.05% -45.82% -49.54% -62.31% -43.20% -31.33% -55.48%
Return on Assets (ROA)		 -3.42% -82.97% -150.36% -99.74% -49.05% -45.81% -49.54% -62.31% -43.20% -30.70% -55.48%
Return on Common Equity (ROCE)		 -26.18% -30.50% -37.09% -42.57% -43.60% -47.99% -52.76% -68.93% -74.28% -78.97% -83.46%
Return on Equity Simple (ROE_SIMPLE)		 -23.74% 0.00% -33.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -10 -26 -32 -30 -27 -27 -30 -33 -21 -20 -18
NOPAT Margin		 -43.29% -736.63% -1,325.71% -879.06% -1,322.46% -1,310.18% -1,276.63% -1,248.77% -936.31% -505.38% -767.46%
Net Nonoperating Expense Percent (NNEP)		 0.06% -2.35% -2.77% -2.33% -2.28% -2.59% -3.46% -8.23% -3.10% -3.27% -3.94%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.11% -9.38% -9.81% -9.52% -10.76% -13.83% -20.05% -14.51% -16.30% -18.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 41.04% 273.22% 602.84% 331.55% 486.22% 504.96% 413.73% 390.06% 418.43% 217.69% 336.50%
R&D to Revenue		 120.80% 879.12% 1,391.03% 1,024.25% 1,503.01% 1,466.73% 1,510.03% 1,038.32% 1,019.15% 604.29% 859.87%
Operating Expenses to Revenue		 161.84% 1,152.33% 1,993.87% 1,355.80% 1,989.23% 1,971.69% 1,923.76% 1,883.95% 1,437.58% 821.97% 1,196.37%
Earnings before Interest and Taxes (EBIT)		 -10 -34 -41 -38 -35 -35 -40 -54 -28 -27 -25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -32 -42 -38 -35 -35 -39 -53 -27 -27 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.06 0.00 1.35 0.48 0.63 0.57 0.39 0.71 1.53 1.22 1.80
Price to Tangible Book Value (P/TBV)		 1.06 0.00 1.35 0.48 0.63 0.57 0.39 0.71 1.53 1.22 1.80
Price to Revenue (P/Rev)		 12.19 0.00 13.90 4.47 15.43 14.41 8.56 12.85 23.34 13.32 16.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.51 0.00 3.31 0.00 0.00 0.00 0.00 0.00 6.20 0.52 5.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.05 -1.05 -1.07 -1.02 -1.03 -1.03 -1.06 -1.06 -1.07 -1.06
Leverage Ratio		 1.19 1.20 1.21 1.25 1.18 1.20 1.21 1.25 1.27 1.30 1.32
Compound Leverage Factor		 1.19 1.20 1.21 1.25 1.18 1.20 1.21 1.25 1.27 1.30 1.32
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.32 0.00 3.77 0.53 0.42 -0.19 -1.21 -2.03 -1.28 -2.71 -3.15
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.27 11.97 10.49 8.75 7.38 7.16 7.63 6.66 5.54 5.71 6.22
Quick Ratio		 13.92 11.70 10.22 8.52 7.15 6.90 7.38 6.44 5.32 5.56 6.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -30 -38 -42 -51 -24 -33 -36 -26 -12 -4.96 -5.83
Operating Cash Flow to CapEx		 -605.81% -938.91% -2,569.27% -1,466.58% -4,853.05% -6,847.49% -3,524.47% -6,760.29% -21,900.00% 0.00% -37,477.78%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.08 0.09 0.09 0.09 0.03 0.03 0.03 0.03 0.03 0.05 0.05
Accounts Receivable Turnover		 10.53 14.21 11.43 15.75 4.29 4.42 4.34 4.59 4.72 5.49 6.22
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.71 2.38 2.10 1.88 0.63 0.53 0.53 0.65 0.68 0.86 0.91
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 34.66 25.68 31.93 23.18 85.01 82.67 84.17 79.45 77.30 66.50 58.71
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 34.66 25.68 31.93 23.18 85.01 82.67 84.17 79.45 77.30 66.50 58.71
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.20 -12 -10 -11 -9.08 -5.71 -4.04 -18 -18 -21 -17
Invested Capital Turnover		 -2.13 -1.94 -2.17 -1.60 -1.50 -1.14 -1.37 -0.64 -0.70 -0.85 -1.08
Increase / (Decrease) in Invested Capital		 20 12 10 20 -2.88 6.05 6.35 -7.35 -8.43 -15 -13
Enterprise Value (EV)		 18 0.00 111 -173 -113 -115 -137 -67 58 5.77 65
Market Capitalization		 422 0.00 464 148 177 144 85 117 217 149 184
Book Value per Share		 $4.51 $4.99 $3.80 $3.44 $3.11 $2.79 $2.34 $1.79 $1.52 $1.31 $1.06
Tangible Book Value per Share		 $4.51 $4.99 $3.80 $3.44 $3.11 $2.79 $2.34 $1.79 $1.52 $1.31 $1.06
Total Capital		 398 368 343 310 281 253 217 166 142 122 102
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -404 -380 -354 -321 -290 -259 -222 -184 -159 -143 -119
Capital Expenditures (CapEx)		 4.75 2.28 1.45 2.24 0.67 0.52 1.04 0.42 0.12 -0.22 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -18 -18 -22 -23 -21 -20 -20 -20 -20 -15
Debt-free Net Working Capital (DFNWC)		 326 311 275 240 205 189 189 164 127 120 103
Net Working Capital (NWC)		 326 311 275 240 205 189 189 164 127 120 103
Net Nonoperating Expense (NNE)		 -0.24 8.30 9.03 7.25 7.92 8.28 9.95 21 6.97 6.57 6.69
Net Nonoperating Obligations (NNO)		 -404 -380 -354 -321 -290 -259 -221 -184 -159 -143 -119
Total Depreciation and Amortization (D&A)		 -0.87 2.36 -0.83 -0.09 -0.05 0.17 0.71 0.87 0.40 0.52 0.38
Debt-free, Cash-free Net Working Capital to Revenue		 -35.73% -53.04% -55.37% -65.57% -199.66% -208.23% -197.95% -222.88% -213.14% -174.94% -133.16%
Debt-free Net Working Capital to Revenue		 942.25% 900.71% 824.73% 724.60% 1,788.82% 1,888.39% 1,903.93% 1,793.87% 1,371.15% 1,073.73% 916.79%
Net Working Capital to Revenue		 942.25% 900.71% 824.73% 724.60% 1,788.82% 1,888.39% 1,903.93% 1,793.87% 1,371.15% 1,073.73% 916.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.32) ($0.46) ($0.42) ($0.38) ($0.39) ($0.43) ($0.58) ($0.30) ($0.28) ($0.26)
Adjusted Weighted Average Basic Shares Outstanding		 83.78M 73.81M 89.30M 90.34M 90.46M 90.32M 92.68M 93.03M 93.29M 93.39M 95.86M
Adjusted Diluted Earnings per Share		 ($0.12) ($0.32) ($0.46) ($0.42) ($0.38) ($0.39) ($0.43) ($0.58) ($0.30) ($0.28) ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding		 83.78M 73.81M 89.30M 90.34M 90.46M 90.32M 92.68M 93.03M 93.29M 93.39M 95.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 88.43M 90.31M 90.32M 90.36M 90.55M 93.00M 93.00M 93.12M 93.47M 96.64M 99.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -26 -32 -30 -27 -27 -30 -25 -21 -20 -18
Normalized NOPAT Margin		 -43.29% -736.63% -1,325.71% -879.06% -1,322.46% -1,310.18% -1,276.63% -929.87% -936.31% -505.38% -767.46%
Pre Tax Income Margin		 -42.27% -964.36% -1,697.57% -1,088.25% -1,713.64% -1,709.15% -1,699.58% -2,028.42% -1,253.32% -686.07% -1,046.52%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Caribou Biosciences (NASDAQ: CRBU) continues to look like a cash-rich, pre-commercial biotech company, but one with very heavy operating losses and no signs yet of meaningful revenue scale. Over the last four years, the company has relied on its balance sheet and investment portfolio to fund research and development, while burning substantial cash each quarter.

  • Strong liquidity remains a key strength. As of Q1 2026, Caribou held $12.1 million in cash and equivalents plus $105.6 million in short-term investments, with another $1.0 million in long-term investments.
  • The balance sheet still shows more assets than liabilities. Total assets were $149.0 million versus total liabilities of $47.0 million in Q1 2026, leaving shareholders’ equity at about $102.0 million.
  • Investing activity generated cash in Q1 2026. Net cash from investing activities was a positive $24.0 million, helped by $46.1 million of investment maturities and sales.
  • Revenue has been stable in the low-single-digit millions quarter to quarter. Q1 2026 revenue of $2.4 million was similar to recent quarters, showing the company is still generating some operating revenue.
  • Operating cash burn improved versus the prior quarter. Cash used in operations was $27.0 million in Q1 2026, better than $20.8 million in Q4 2025 and well below some earlier periods in 2025 and 2024.
  • Share count continues to trend higher. Weighted average diluted shares rose to 95.9 million in Q1 2026 from 93.4 million in Q3 2025, suggesting ongoing dilution.
  • Deferred revenue provides some visibility, but it is modest. Current and noncurrent deferred revenue totaled about $2.6 million in Q1 2026, a small cushion relative to the company’s spending.
  • Capital expenditures are minimal. Q1 2026 purchases of property and equipment were only $72,000, which is typical for a research-focused biotech company.
  • Caribou is still deeply unprofitable. Q1 2026 net loss was $25.1 million, with operating loss of $26.3 million.
  • Research and development remains the biggest cost driver. Q1 2026 R&D expense was $20.6 million, far exceeding revenue and keeping losses elevated.
  • Gross revenue is nowhere close to covering expenses. Q1 2026 revenue of $2.4 million versus operating expenses of $28.7 million underscores the company’s dependence on its cash reserves.
  • Liquidity has declined materially over the past year. Total current assets fell from $217.3 million in Q1 2025 to $122.4 million in Q1 2026, largely due to the use of investments and cash to fund operations.
  • Long-term decline in cash reserves is clear. Cash and equivalents dropped from $49.4 million in Q1 2024 to $12.1 million in Q1 2026.
  • Accumulated losses remain very large. Retained earnings were negative $621.6 million in Q1 2026, highlighting years of losses.

Bottom line: Caribou Biosciences has enough liquidity for now and a clean net cash position, but the core story is still one of heavy burn and limited revenue. Investors should watch the pace of cash use, the size of the investment portfolio, and whether the company can advance its pipeline toward value-creating clinical milestones before dilution or additional financing becomes a bigger issue.

07/06/26 10:01 AM ETAI Generated. May Contain Errors.

Caribou Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Caribou Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Caribou Biosciences' net income appears to be on an upward trend, with a most recent value of -$148.13 million in 2025, rising from -$23.43 million in 2019. The previous period was -$149.11 million in 2024. See where experts think Caribou Biosciences is headed by visiting Caribou Biosciences' forecast page.

Caribou Biosciences' total operating income in 2025 was -$148.34 million, based on the following breakdown:
  • Total Gross Profit: $11.16 million
  • Total Operating Expenses: $159.50 million

Over the last 6 years, Caribou Biosciences' total revenue changed from $5.79 million in 2019 to $11.16 million in 2025, a change of 92.8%.

Caribou Biosciences' total liabilities were at $53.19 million at the end of 2025, a 11.9% decrease from 2024, and a 192.9% increase since 2020.

In the past 5 years, Caribou Biosciences' cash and equivalents has ranged from $12.36 million in 2025 to $240.42 million in 2021, and is currently $12.36 million as of their latest financial filing in 2025.

Over the last 6 years, Caribou Biosciences' book value per share changed from 0.00 in 2019 to 1.31 in 2025, a change of 130.7%.


Related Companies

Financial statements for NASDAQ:CRBU last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
He’s Back. And He’s About to Act
The U.S. government holds 8,133 tonnes of gold valued at just $42.22 an ounce on its books - while gold trades...
Priority Gold | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Move your money (NOT into the next AI IPO)
While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...
Stansberry Research | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel